Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel versus weekly paclitaxel as neoadjuvant therapy for operable triple-negative or luminal B/HER2-negative breast cancer
2012-003330-16Phase 2Completed
- Sponsor
- GBG Forschungs
- Start
- Nov 2012
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer and triple-negative breast cancer (TNBC) comparing Cabazitaxel with Weekly paclitaxel (2 arms). Primary endpoint: Pathologic complete response in the breast. Started Nov 2012; status: completed.
02
Drugs
cabazitaxelpaclitaxel
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2012-003330-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003330-16.